Economic evaluation of varicella vaccination : Results of a systematic review

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1932-1942

  Unim, Brigid ^a   Saulle, Rosella ^a   Boccalini, Sara ^b   Taddei, Cristina ^b   Ceccherini, Vega ^b   Boccia, Antonio ^a   Bonanni, Paolo ^b   La Torre, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cost benefit; Cost effectiveness; Cost utility; Economic evaluation; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE;

CHICKENPOX; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; QUALITATIVE ANALYSIS; QUALITY CONTROL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; VACCINATION;

COST BENEFIT; COST EFFECTIVENESS; COST UTILITY; ECONOMIC EVALUATION; VACCINATION; VARICELLA;

CHICKENPOX; CHICKENPOX VACCINE; COST-BENEFIT ANALYSIS; HUMANS; ITALY; VACCINATION;

EID: 84884612068     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25228     Document Type: Review

References (48)

1. Epicentro: Il portale dell'epidemiologia per la sanità pubblica. Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute. Available at: http://www.epicentro.iss.it/problemi/varicella/varicella. asp; last access 19.11.12.
2. Presidente del Consiglio dei Ministri. D.P.C.M. Definizione dei livelli essenziali di assistenza. G.U.8 Febbraio 2002, n.33, S.
3. Institut RK. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: Juli 2006. Epidemiol Bull 2006; 30:235-54
4. Childhood immunisation calendar, Greece. Available at: http://www.mohaw.gr/gr/thefuture/anakoinoseis/Timetable%202008.xls
5. Macartney KK, Burgess MA. Varicella vaccination in Australia and New Zealand. J Infect Dis 2008; 197(Suppl 2):S191-5; PMID:18419396; http://dx.doi.org/10.1086/522157
6. National Advisory Committee on Immunization. National Advisory Committee on Immunization (NACI) update on varicella. Can Commun Dis Rep 2004; 30:1-26; PMID:14964716
7. Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008; 197(Suppl 2):S185-90; PMID:18419395; http://dx.doi.org/10.1086/522163
8. WHO vaccine preventable disease monitoring system: Immunization schedules by antigen, selection centre. Available at: http/www.who.int/immunization- monitoring/en/globalsummary/scheduleselect.cfm
9. Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1-40; PMID:17585291
10. Alfonsi V, D'Ancona F, Giambi C, Nacca G, Rota MC; Regional Coordinators for Infectious Diseases and Vaccinations. Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy. Health Policy 2011; 103:176-83; PMID:22030308; http://dx.doi.org/10.1016/j. healthpol.2011.10.002
11. Bernaola Iturbe E, Giménez Sánchez F, Baca Cots M, de Juan Martín F, Díez Domingo J, Garcés Sánchez M, et al.; Spanish Association of Pediatrics. Vaccination schedule of the Spanish Association of Pediatrics: recommendations 2007. An Pediatr (Barc) 2007; 66:62-9; PMID:17266854
12. Vesikari T, Baer M, Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Pediatr Infect Dis J 2007; 26:153-8; PMID:17259879; http://dx.doi.org/10. 1097/01.inf.0000250689.09396.21
13. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, et al. Varicella vaccination in Europe - taking the practical approach. BMC Med 2009; 7:26; PMID:19476611; http://dx.doi.org/10.1186/1741-7015-7-26
14. Shapiro ED, Vazquez M, Esposito D, Holabird N, Steinberg SP, Dziura J, et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011; 203:312-5; PMID:21208922; http://dx.doi.org/10.1093/infdis/jiq052
15. Kattan JA, Sosa LE, Bohnwagner HD, Hadler JL. Impact of 2-dose vaccination on varicella epidemiology: Connecticut - 2005-2008. J Infect Dis 2011; 203:509-12; PMID:21199882; http://dx.doi.org/10.1093/infdis/jiq081
16. Committee on Infectious Diseases. Policy statement - Prevention of varicella: update of recommendations for use of quadrivalent and monovalent varicella vaccines in children. Pediatrics 2011; 128:630-2; PMID:21873692; http://dx.doi.org/10.1542/peds.2011-1968
17. Gruppo di lavoro ICONA. ICONA 2008: Indagine di Copertura vaccinale Nazionale nei bambini e negli adolescenti. Rapporti ISTISAN 09/29. Istituto Superiore di Sanità, Roma; 2009.
18. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:689-96; PMID:22951450
19. Ward K, Dey A, Hull B, Quinn HE, Macartney K, Menzies R. Evaluation of Australia's varicella vaccination program for children and adolescents. Vaccine 2013; 31:1413-9; PMID:23290837; http://dx.doi.org/10.1016/j.vaccine.2012.12.052
20. Ozaki T. Varicella vaccination in Japan: necessity of implementing a routine vaccination program. J Infect Chemother 2013; 19:188-95; PMID:23483311; http://dx.doi.org/10.1007/s10156-013-0577-x
21. Piano Nazionale Prevenzione vaccinale 2012-2014. Ministero della salute. Available at: http://www.salute.gov.it/dettaglio/phPrimoPianoNew.jsp?id=339; last access 19.11.12.
22. Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med 1999; 49:763-79; PMID:10459888; http://dx.doi.org/10.1016/S0277-9536(99)00115-X
23. Scuffham PA, Lowin AV, Burgess MA. The costeffectiveness of varicella vaccine programs for Australia. Vaccine 1999; 18:407-15; PMID:10519929; http://dx.doi.org/10.1016/S0264-410X(99)00261-3
24. Díez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17:1306-11; PMID:10195765; http://dx.doi.org/10.1016/S0264-410X(98)00394-6
25. Coudeville L, Paree F, Lebrun T, Sailly JC. The value of varicella vaccination in healthy children: costbenefit analysis of the situation in France. Vaccine 1999; 17:142-51; PMID:9987148; http://dx.doi.org/10.1016/S0264- 410X(98)00161-3
26. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20:1113-25; PMID:11803072; http://dx.doi.org/10.1016/ S0264-410X(01)00437-6
27. Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol 2002; 191:89-96; PMID:12410347; http://dx.doi.org/10.1007/s00430-002-0123-4
28. Getsios D, Caro JJ, Caro G, De Wals P, Law BJ, Robert Y, et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J 2002; 21:542-7; PMID:12182379; http://dx.doi.org/10.1097/00006454-200206000-00012
29. Hsu HC, Lin RS, Tung TH, Chen TH. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine 2003; 21:3982-7; PMID:12922134; http://dx.doi.org/10.1016/ S0264-410X(03)00270-6
30. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003; 88:862-9; PMID:14500303; http://dx.doi.org/10.1136/adc.88.10.862
31. Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 2003; 21:1256-67; PMID:12559807; http://dx.doi.org/10.1016/S0264- 410X(02)00431-0
32. Hanslik T, Boëlle PY, Schwarzinger M, Carrat F, Freedberg KA, Valleron AJ, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 2003; 21:3614-22; PMID:12922090; http://dx.doi.org/10.1016/S0264-410X(03)00405-5
33. Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 2004; 22:3546-62; PMID:15315834; http://dx.doi.org/10.1016/j.vaccine. 2004.03.043
34. Ginsberg GM, Somekh E. Cost containment analysis of childhood vaccination against varicella in Israel. J Infect 2004; 48:119-33; PMID:14720487; http://dx.doi.org/10.1016/S0163-4453(03)00079-3
35. Jean-Jasmin LM, Lynette SP, Stefan M, Kai CS, Chew FT, Wah LB. Economic burden of varicella in Singapore-a cost benefit estimate of implementation of a routine varicella vaccination. Southeast Asian J Trop Med Public Health 2004; 35:693-6; PMID:15689089
36. Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 2004; 22:839-55; PMID:15329030; http://dx.doi.org/10.2165/ 00019053-200422130-00003
37. Tseng HF, Tan HF, Chang CK. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan. Southeast Asian J Trop Med Public Health 2005; 36:1450-8; PMID:16610647
38. Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 2005; 8:209-22; PMID:15877593; http://dx.doi.org/10.1111/j.1524-4733.2005.04005.x
39. Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 2006; 24:6980-9; PMID:16860909; http://dx.doi.org/10.1016/j.vaccine. 2006.04.051
40. Hammerschmidt T, Bisanz H, Wutzler P. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine 2007; 25:7307-12; PMID:17881097; http://dx.doi.org/10.1016/j.vaccine.2007.08.017
41. Valentim J, Sartori AMC, de Soárez PC, Amaku M, Azevedo RS, Novaes HM. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 2008; 26:6281-91; PMID:18674582; http://dx.doi.org/10.1016/j.vaccine.2008.07.021
42. Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis 2008; 197(Suppl 2):S156-64; PMID:18419391; http://dx.doi.org/10.1086/522135
43. Bonanni P, Boccalini S, Bechini A, Banz K. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. Vaccine 2008; 26:5619-26; PMID:18723062; http://dx.doi.org/10.1016/j.vaccine. 2008.07.096
44. Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin 2009; 5:847-57; PMID:19829048
45. Bonanni P. Italie-la politique de vaccination. Vax Info 2003; 36:6-8
46. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Int J Public Health 2009; 4:94-131
47. Drummond MF, Jefferson TO; The BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313:275-83; PMID:8704542; http://dx.doi.org/10.1136/bmj.313.7052.275
48. La Torre G, Nicolotti N, de Waure C, Ricciardi W. Development of a weighted scale to assess the quality of cost-effectiveness studies and an application to the economic evaluations of tetravalent HPV vaccine.Int J Public Health 2011; 19:103-11; http://dx.doi.org/10.1007/s10389-010-0377-z